ADMA Earnings Prediction
The chart below shows how ADMA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ADMA sees a +3.73% change in stock price 10 days leading up to the earnings, and a +23.82% change 10 days following the report. On the earnings day itself, the stock moves by +0.38%. This data can give you a slight idea of what to expect for the next quarter's release.
ADMA Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
119.84M
78.13%
11.80%
Gross Margin
49.76%
36.78%
-6.94%
Operating Margin
33.08%
156.24%
-9.54%
Net Margin
29.96%
686.35%
0.17%
EPS
0.15
1400.00%
15.38%
No Data Available
ADMA Earnings Analysis
ADMA Biologics, Inc. Corporation (ADMA.O) Earnings Conference Call
Positive
Revenue Increase of 78%: Total revenues reached $119.8 million reflecting an increase of 78% year-over-year.
EBITDA and Net Income Surge: Adjusted EBITDA rose to $45.4 million, representing a growth rate of 256% from the previous year, while net income increased by 1,300% year-over-year to $35.9 million.
Gross Margin Improvement: The company achieved a corporate gross margin of 50% in the third quarter of 2024 compared to 37% in the third quarter of 2023.
Revenue and EBITDA Projections: We expect total revenues to exceed $415 million in 2024 and $465 million in 2025 with adjusted EBITDA projected to surpass $160 million and $215 million respectively in 2024 and 2025.
Pilot-Scale Production Success: We successfully completed product production of a pilot-scale batch of SG-001, further solidifying our position in the market.
Negative
Quarterly Revenue Increase: Total revenues reached $119.8 million for the quarter ended September 30, 2024, compared to $67.3 million for the quarter ended September 30, 2023, an increase of $52.6 million, or approximately 78%.
Gross Profit Increase: Gross profits were $59.7 million for the quarter ended September 30, 2024 as compared to $24.7 million for the quarter ended September 30, 2023, an increase of $35 million.
Gross Margin Improvement: A DMA achieved a corporate gross margin of 50% in the third quarter of 2024 as compared to 37% in the third quarter of 2023.
Gross Margin Impact: Third quarter 2024 corporate gross margins were adversely impacted due to an outsized spot sale of low margin normal source plasma.
EBITDA Surge Quarter Comparison: During the third quarter, adjusted EBITDA was $45.4 million as compared to adjusted EBITDA of $12.7 million for the quarter ended September 30, 2023, an increase of $32.6 million or approximately 256%.
ADMA FAQs
How does ADMA typically perform around its earnings report dates?
Is ADMA Biologics, Inc. (ADMA) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ADMA Earning Call Sentiment
ADMA Biologics, Inc. (ADMA) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
ADMA.O
-4.68%Positive
ADMA's earnings call reveals strong financial performance with significant revenue growth and improved margins, alongside optimistic guidance for 2024 and 2025. Despite competitive pressures and supply chain challenges, the company's strategic initiatives like the VIP donor program and anticipated ASCENIV pediatric label expansion are promising. The Q&A section highlighted some concerns about plasma supply but overall sentiment remains positive, supported by increased net income and EBITDA guidance. Given the mid-cap status, the stock is likely to experience a positive movement of 2% to 8% over the next two weeks.
